Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

March 31, 2026

Conditions
Partial Epilepsy
Interventions
DRUG

Xcopri

Xcopri will be administered orally not to exceed 400mg/day adult equivalent

Trial Locations (14)

20817

RECRUITING

Mid-Atlantic Epilepsy and Sleep Center, Bethesda

27705

RECRUITING

Duke University, Durham

38103

RECRUITING

Le Bonheur Children's Hospital, Memphis

45229

RECRUITING

Cincinnati Children's Hospital, Cincinnati

65201

TERMINATED

Missouri University Pediatric and Adolescent Specialty Clinic, Columbia

85016

RECRUITING

Phoenix Children's Hospital, Phoenix

98405

RECRUITING

MultiCare Institute - Mary Bridge Children's Neurology, Tacoma

07601

RECRUITING

Northeast Regional Epilepsy Group, Hackensack

07960

WITHDRAWN

Northeast Regional Epilepsy Group, Morristown

Unknown

RECRUITING

I. Sz. Gyermekgyógyászati Klinika, Budapest

RECRUITING

Chungbuk National University Hospital, Cheonju

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital, Seoul

RECRUITING

Ajou University Hospital, Suwon

All Listed Sponsors
lead

SK Life Science, Inc.

INDUSTRY

NCT04903314 - Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures | Biotech Hunter | Biotech Hunter